The inaugural Global AMR Innovators Conference (GAMRIC) took place in London from 1-3 October 2025. Here, the AMR research community convened for high-level discussions on the latest breakthroughs and challenges of developing new therapeutics, diagnostics, vaccines and preventatives addressing AMR.
Recordings are available on the ESCMID website via the links below (Log-in required upon free registration). You can also find a comprehensive round-up of the conference on the ESCMID website here.
Day 1
The Global AMR Crisis: Understanding the problem and developing a solution
Chair: Erin Duffy, USA
- Charlotte Watts, UK
- David Paterson, Singapore
- Sam Barrell, UK
- Marc Gitzinger, Switzerland
Developing antibacterial therapies to address unmet medical need in neonates
Chair: Sumati Nambiar, USA
- Children are not little adults: What is needed to reduce the rising global child neonatal mortality burden caused by multidrug-resistant sepsis?
- Phoebe Williams, Australia
- Uncommon patients and uncharted pathways: Exploring novel approaches in developing neonatal therapeutics and ethical considerations
- Seun Makinde, USA
- Clinical Pharmacology considerations in neonatal antimicrobial drug development
- Chris Darlow, UK
- Anxious parents of sick babies do not want additional risk for research
- John Bradley, USA
- Q&A – Featuring all of the above and Seamus O’ Brien and Gary Noel
The Global health and AMR challenges of sexually transmitted infections: A focus on interventions
Chair: Seamus O’ Brien, UK
- STIs and AMR: Challenges and potential opportunities
- Carolyn Deal, USA
- STIs challenges and research needs in resource-constrained settings
- Sinead Delany-Moretlwe, South Africa
- Develoment of Antibiotics for Gonorrhoea: Where are we in 2025?
- Alison Luckey, UK
- Opportunities for vaccines in gonorrhoea
- Susanne Hodgson, UK
- Q&A – Featuring all of the above
Policy and implementation: What progress since UNGA 2024? Are we on track for UNGA 2029?
Chair: Lotte Steuten, UK
- The economics of AMR – Why does the market for antimicrobials need to be fixed?
- Jorge Mestre-Ferandiz, Spain
- How is policy made? Solving the political and policy problems that prevent AMR solutions
- Robert Horne, USA
- How is Europe looking for a solution for AMR in its complex setting
- Marc Gitzinger, Swizerland
- From jargon to action: Improving AMR messaging for policy and public impact
- Eva Krockow, UK
- Q&A – Featuring all of the above
Day 2
Addressing the challenges of lower respiratory tract infections
Chair: Valeria Gigante, Switzerland
- Clinical: Overview of LRTIs and clinical cases
- Stephan Harbarth, Switzerland
- R&D: Challenges and opportunity for doing HABP/VABP clinical trials
- Mo Yin, Singapore
- Accelerating diagnosis, enhancing stewardship: Rapid molecular testing for nosocomial pneumonia in the ICU
- Virve Enne, UK
- Respiratory tract infections in children in LMICs
- Phuc Phan Huu, Vietnam
- Q&A – Featuring all of the above
Breaking from traditional R&D practices to optimize tuberculosis drug discovery
Chair: Kelly Chibale, South Africa
- TBDA model for global health
- Steve Berthel, USA
- Genetic approaches to facilitate antibacterial drug development
- Dirk Schnappinger, USA
- Design and patterns of optimized drug combinations for TB
- Bree Aldridge, USA
- Lesion-centric pharmacokinetic (PK) & pharmacodynamic (PD) considerations for TB drug discovery and regimen design
- Jansy Sarathy, USA
- Q&A – Featuring all of the above
Defining the challenges in antifungal drug R&D
Chair: John Rex, USA
- The antifungal pipeline: Why is antifungal discovery so hard?
- Carole Sable, USA
- PK/PD for fungi: There’s still a lot to learn
- Shampa Das, UK
- Clinical development: The trial(s) you want vs. the trial(s) you can do
- Sumati Nambiar, USA
- Development for very rare fungal pathogens: Is this possible?
- Radu Botgros, Netherlands and John Rex, USA
- Q&A – Featuring all of the above
Extracting value from diagnostics in the management of AMR infections: How can developers create products that achieve widespread global use?
Chair: Robert Skov, Denmark and Holger Rohde, Germany
- Gaps at the systems, provider and product level
- Chantal Morel, Switzerland
- The value of diagnostics against AMR
- Lotte Steuten, UK
- Rising to the challenge: A summary of outcomes
- Robert Skov, Denmark
- Q&A – Featuring all of the above
Special lecture: Mirror bacteria – a future threat
Chair: John Rex, USA
- Special Lecture: Mirror Bacteria – A future threat
- Vaughn Cooper, USA
- Q&A – Featuring all of the above
Day 3
Understanding the multidisciplinary interactions in healthcare centers: The patient and the product journey in different resource settings
Addressing the challenges of lower respiratory tract infections
- Part 1: Low income country
- Brian Nzano (Chair), USA
- Mbabazi Phoebe Kalungu, Uganda
- Namugema Bernadett, Uganda
- Part 2: Middle income country
- Taslimarif Saiyed (Co-chair), India
- Anand Anandkumar (Co-Chair), India
- George Varghese, India
- Vijay Richard, India
- Mallika Reddy, India
Understanding the multidisciplinary interactions in healthcare centers: The patient and the product journey in different resources settings
- Part 3: High income country
- Betsy Wonderly-Trainor (Chair), USA
- Suzane Silbert, USA
- Kristen Atrubin, USA
- Heinz Salazar, USA
- Kartikeya Cherabuddi, USA
- Summary discussion and lessons learned
- Betsy Wonderly-Trainor, USA
- Anand Anandkumar, India
- Taslimarif Saiyed, India
- Brian Nzano, USA
Jointly organized by: 